HomeCompareTRSDX vs JNJ

TRSDX vs JNJ: Dividend Comparison 2026

TRSDX yields 22.71% · JNJ yields 3.36%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 TRSDX wins by $66.1K in total portfolio value
10 years
TRSDX
TRSDX
● Live price
22.71%
Share price
$8.81
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$86.1K
Annual income
$8,911.27
Full TRSDX calculator →
JNJ
Johnson & Johnson
● Live price
3.36%
Share price
$147.50
Annual div
$4.96
5Y div CAGR
5.8%
Payout ratio
55%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.0K
Annual income
$827.78
Full JNJ calculator →

Portfolio growth — TRSDX vs JNJ

📍 TRSDX pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodTRSDXJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, TRSDX + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
TRSDX pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

TRSDX
Annual income on $10K today (after 15% tax)
$1,930.30/yr
After 10yr DRIP, annual income (after tax)
$7,574.58/yr
JNJ
Annual income on $10K today (after 15% tax)
$285.83/yr
After 10yr DRIP, annual income (after tax)
$703.61/yr
At 15% tax rate, TRSDX beats the other by $6,870.97/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of TRSDX + JNJ for your $10,000?

TRSDX: 50%JNJ: 50%
100% JNJ50/50100% TRSDX
Portfolio after 10yr
$53.1K
Annual income
$4,869.52/yr
Blended yield
9.18%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

TRSDX
No analyst data
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
+55.1% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

TRSDX buys
0
JNJ buys
0
No recent congressional trades found for TRSDX or JNJ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricTRSDXJNJ
Forward yield22.71%3.36%
Annual dividend / share$2.00$4.96
Payout ratio50%55%
1-year div growth0%4.2%
5-year div CAGR0%5.8%
Portfolio after 10y$86.1K$20.0K
Annual income after 10y$8,911.27$827.78
Total dividends collected$52.1K$5.6K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: TRSDX vs JNJ ($10,000, DRIP)

YearTRSDX PortfolioTRSDX Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$12,971$2,270.95$10,676$355.77+$2.3KTRSDX
2$16,632$2,752.93$11,407$389.39+$5.2KTRSDX
3$21,095$3,298.98$12,198$426.53+$8.9KTRSDX
4$26,482$3,910.53$13,056$467.62+$13.4KTRSDX
5$32,924$4,588.03$13,987$513.12+$18.9KTRSDX
6$40,560$5,330.91$14,998$563.56+$25.6KTRSDX
7$49,536$6,137.59$16,098$619.52+$33.4KTRSDX
8$60,010$7,005.59$17,295$681.69+$42.7KTRSDX
9$72,142$7,931.53$18,599$750.82+$53.5KTRSDX
10$86,103$8,911.27$20,022$827.78+$66.1KTRSDX

TRSDX vs JNJ: Complete Analysis 2026

TRSDXStock

The investment seeks long-term capital appreciation. The fund invests at least 80% of its net assets, plus any borrowings for investment purposes, in common stocks of small and mid-capitalization companies organized in the United States that the Adviser believes should generate excess returns, as compared to the Russell 2500TM Growth Index, with below-market risk over time, namely companies with superior operating and financial characteristics and proven records of increasing earnings on a consistent and sustainable basis.

Full TRSDX Calculator →

JNJHealthcare

Johnson & Johnson is a Dividend King with 62+ years of consecutive dividend increases. A healthcare conglomerate spanning pharmaceuticals, MedTech, and consumer health. JNJ spun off its consumer segment as Kenvue in 2023, focusing on higher-margin pharma and medical devices.

Full JNJ Calculator →
📬

Get this TRSDX vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

TRSDX vs SCHDTRSDX vs JEPITRSDX vs OTRSDX vs KOTRSDX vs MAINTRSDX vs ABBVTRSDX vs MRKTRSDX vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.